Background: Persons with diabetes mellitus (DM) exhibit a higher rate of depressive illness than does the general US population. Despite this finding, previous research has documented a low rate of diagnosis and/or treatment with antidepressant pharmacotherapy among persons with DM.
Objective: The aim of this study was to examine the current rate of diagnosis of depression and use of antidepressant pharmacotherapy among persons with DM.
Results: We examined data from the 2005 US National Ambulatory Medical Care Survey. In 2005, there were an estimated 35,345,845 persons with an office-based visit for DM and, of these, 3,823,508 (10.8%) had a concomitant diagnosis of depression. Within this subset, 1,830,620 (47.9%) were prescribed antidepressant pharmacotherapy.
Conclusion: Our findings serve to quantify the prevalence of a diagnosis of depression and use of antidepressant pharmacotherapy for its treatment among persons with DM in the United States.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969981 | PMC |
| http://dx.doi.org/10.1016/j.curtheres.2009.12.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial.
EClinicalMedicine
October 2024
Centre for Psychedelic Research, Division of Psychiatry, Department Brain Sciences, Imperial College London, United Kingdom.
Background: Psilocybin therapy (PT) produces rapid and persistent antidepressant effects in major depressive disorder (MDD). However, the long-term effects of PT have never been compared with gold-standard treatments for MDD such as pharmacotherapy or psychotherapy alone or in combination.
Methods: This is a 6-month follow-up study of a phase 2, double-blind, randomised, controlled trial involving patients with moderate-to-severe MDD.
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common pediatric psychiatric disorders and is frequently diagnosed and treated by pediatricians. Stimulant medications are the first-line treatment for ADHD but may not be a good fit for many patients due to side effects, inadequate treatment response, or family preference. Non-stimulant ADHD medications provide a useful alternative for patients that cannot tolerate stimulants, have an incomplete treatment response to stimulants, are at risk for stimulant diversion, or whose family prefers to avoid stimulants.
View Article and Find Full Text PDFNeuroimaging signatures and a deep learning modeling for early diagnosing and predicting non-pharmacological therapy success for subclinical depression comorbid sleep disorders in college students.
Int J Clin Health Psychol
December 2024
First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Objective: College students with subclinical depression often experience sleep disturbances and are at high risk of developing major depressive disorder without early intervention. Clinical guidelines recommend non-pharmacotherapy as the primary option for subclinical depression with comorbid sleep disorders (sDSDs). However, the neuroimaging mechanisms and therapeutic responses associated with these treatments are poorly understood.
View Article and Find Full Text PDFPredicting Antidepressant Treatment Response From Cortical Structure on MRI: A Mega-Analysis From the ENIGMA-MDD Working Group.
Hum Brain Mapp
January 2025
Amsterdam UMC, Department of Radiology and Nuclear Medicine, University of Amsterdam, Amsterdam, the Netherlands.
Accurately predicting individual antidepressant treatment response could expedite the lengthy trial-and-error process of finding an effective treatment for major depressive disorder (MDD). We tested and compared machine learning-based methods that predict individual-level pharmacotherapeutic treatment response using cortical morphometry from multisite longitudinal cohorts. We conducted an international analysis of pooled data from six sites of the ENIGMA-MDD consortium (n = 262 MDD patients; age = 36.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!